Overview

Safety and Efficacy Study for MG-7-DC Vaccine in Gastric Cancer Treatment

Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to determine the safety and efficacy of autologous DC vaccine in patients with later stage of gastric cancer. The DC vaccine is gene modified with gastric cancer specific antigen MG-7.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The Second Hospital of Shandong University
Collaborator:
Shandong Sunstem Biotechnology Co.,Ltd.
Treatments:
Vaccines